DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Long GV, Atkinson V, Cebon JS. et al.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Lancet Oncol 2017;
18: 1202-1210
We do not assume any responsibility for the contents of the web pages of other providers.